The aim of the present study was to develop and validate the analytical method for bilayer tablets. Materials and Methods: Simultaneous estimation of fexofenadine hydrochloride (HCl) and montelukast sodium in bilayer tablets by ultraviolet spectrophotometric method. Results and Discussion: The absorption maxima of fexofenadine HCl and montelukast sodium were found to be 259 nm and 285 nm, respectively, using phosphate buffer pH 6.8. The method obeys Beer's law in the concentration range of 24-84 µg/ml and 2-14 µg/ml for fexofenadine HCl and montelukast sodium, respectively. Different analytical parameters such as limit of detection, limit of quantitation, accuracy, and precision were determined as per International Council for Harmonisation guidelines Q2 (R1). Conclusion: The accuracy of the method was found to be 99.71% and 99.13% for fexofenadine HCl and montelukast sodium, respectively. There is no interference shown by the excipients of the formulation in the method and the method can be used for routine quality control.
INTRODUCTION
M ontelukast is a leukotriene receptor antagonist. It is used for the treatment of asthma and seasonal allergies. It is mainly orally administered. It acts by blocking leukotriene D4 on cysteinyl leukotriene receptor CysLT1 present in the bronchial tubes and lungs, which leads to a reduction in bronchoconstriction caused by leukotriene, thus reducing inflammation. It cannot be used for treating acute asthma. [1] It has no interaction with other antiallergic medications like theophylline due to its specificity. Singulair ® is the marketed formulation of montelukast and is marketed in several countries including the United States by Merck & Co. It is available in the form of oral granules, chewable tablets, and oral tablets. Cipla markets montelukast under Figure 2 : Chemical structure of fexofenadine [4] Figure 1: Chemical structure of montelukast [3] the brand name Montair ® in many countries including India. [2] Fexofenadine hydrochloride (HCl) (Allegra) is antihistaminic in nature and is used for treating hay fever and other allergic symptoms. It was developed as an alternative to terfenadine. It does not pass through the blood-brain barrier readily, and hence, drowsiness is less as compared to the first-generation antihistamines. [3] The bilayer tablets of fexofenadine HCl and montelukast sodium were prepared in house. The bilayer tablets of fexofenadine HCl and montelukast sodium were prepared in house to target the release of the drugs in intestine at pH 6.8.
No method was reported for the simultaneous estimation of the fexofenadine and montelukast in the given medium. Hence, the method is best suited for the simultaneous estimation of both of the drugs in the given medium. [5] 
MATERIALS AND METHODS

Instruments
The analytical method for the estimation was performed on ultraviolet spectrophotometer (Shimadzu-1800). Weighing of the other chemicals was done on an analytical balance.
Chemicals and reagents
The drug samples of fexofenadine HCl and montelukast sodium were obtained from Yarrow Chemicals Ltd., Mumbai. A marketed formulation Allegra-M tablet was procured from the market. All other chemicals were of analytical grades.
Preparation of standard stock solutions
Accurately weighed 10 mg each of fexofenadine HCl [ Figure 1 ] and montelukast sodium [ Figure 2 ] were separately dissolved in 1 ml methanol and the volume was made up to 10 ml with pH 6.8 phosphate buffer to obtain solutions of 1000 µg/ml each. These solutions were used as standard stock solutions for further analysis.
Preparation of pH 6.8 phosphate buffer
To a 1000 ml volumetric flask, 250 ml of freshly prepared 0.2 M monobasic potassium phosphate (KH 2 PO 4 ) solution was transferred. To this, 112 ml of 0.2 M sodium hydroxide solution was added. The volume was made up to 1000 ml with distilled water. The pH was checked with the help of a pH meter. The pH was adjusted with orthophosphoric acid if the pH was more than 6.8, and with sodium hydroxide solution, if the pH was below 6.8. [6] 
Preparation of 0.2 M monobasic potassium phosphate solution
Accurately weighed monobasic potassium phosphate (27.22 g) was dissolved in a sufficient quantity of distilled water. The solution was then transferred into a 1000 ml volumetric flask. The volume was made up to 1000 ml with distilled water to get a 0.2 M monobasic potassium phosphate solution.
Preparation of 0.2 M sodium hydroxide solution
Accurately weighed sodium hydroxide pellets (8 g) were dissolved in a sufficient quantity of distilled water taken in a beaker. The solution was then transferred to a 1000 ml volumetric flask and volume was made up to 1000 ml with distilled water to obtain a solution of 0.2 M sodium hydroxide.
RESULTS AND DISCUSSION
Selection of analytical wavelength
From the standard stock solutions, appropriate dilutions were made to obtain final concentrations of 100 µg/ml fexofenadine HCl and 60 µg/ml montelukast sodium. The prepared solutions were then separately scanned in the wavelength range of 200-400 nm. Fexofenadine HCl showed maximum absorbance at 259 nm [ Figure 3 ], while montelukast sodium showed maximum absorbance at 285 nm [ Figure 4 ]. These two wavelengths were selected for further analysis.
The method was developed and validated with respect to linearity, range, accuracy, precision, the limit of detection (LOD), and limit of quantitation (LOQ) as per International Council for Harmonisation (ICH) guidelines. [7, 8] 
Linearity and range
For each drug, appropriate aliquots were pipette out from standard stock solutions into a series of 10 ml volumetric flasks. The volume was made up to the mark with pH 6.8 phosphate buffer. The prepared aliquots for fexofenadine HCl (24-84 µg/ml) were scanned for absorbance at 259 nm [ Figure 5 ]. The absorbance range was noted and determined if these aliquots followed Beer-Lambert's law or not. Similarly, aliquots for montelukast sodium (4-14 µg/ml) were prepared and scanned for absorbance at 285 nm [ Figure 6 ]. The regression coefficients for fexofenadine HCl and montelukast sodium were determined. [9] 
Determination of absorptivity at analytical wavelength
The absorbances obtained for each of the prepared aliquots were divided by their respective concentrations (g/100 ml) to obtain their absorptivity values [ Tables 1 and 2 ]. [10, 11] Absorbane Absorptivity = g Concentration 100 ml
Analysis of a standard mixture
The standard mixture was made in the ratio of 60:10 (fexofenadine HCl: montelukast sodium) from the working Table 3 ]. The concentrations of each drug were calculated by putting the absorbance and absorptivity values in the following equations: 
Precision
The precision of the method was determined with the prepared aliquots. The precision of the method was verified by repeatability (intraday) and intermediate precision (interday) studies [ Table 4 ].
Repeatability
Repeatability studies were performed by analysis of 60 µg/ml standard of fexofenadine HCl and 10 µg/ml of montelukast sodium. Method repeatability was achieved by repeating the same procedure 6 times on the same day for intraday precision. The repeatability of sample application and measurement was expressed in terms of relative standard deviation (% RSD) and standard error (S.E.) [ Table 5 ].
Intermediate precision
The intermediate (interday) precision of the method was checked by performing the same procedure on different days under the same experimental conditions. 
LOD and LOQ
LOD is defined as the lowest amount of analyte that can be detected but may not get quantified. LOQ is the lowest amount of analyte that can be determined quantitatively with high accuracy and precision. To estimate the LOD and LOQ, individual standard deviations were determined of the sex replicates for 60 µg/ml of fexofenadine HCl and 10 µg/ml of montelukast sodium. The LOD and LOQ were then calculated by dividing the standard deviations of intercepts with slopes of their respective calibration curves [ Table 6 ]. 
Accuracy and recovery
Accuracy of the method was validated by preparing three dilutions containing 80%, 100%, and 120% of the actual concentration. Triplicate determinations at each concentration level were executed and the obtained outcomes were compared with the expected outcomes. [11, 12] Percentage recoveries were determined and found satisfactory as shown in Tables 7 and 8 .
Optical characteristics
Fexofenadine hydrochloride and Montelukast sodium were estimated by simultaneous estimation method and their optical characteristics used for the same as represented in Table 9 . The absorbance were recorded for the Fexofenadine hydrochloride and Montelukast sodium at 259 nm and 285 nm showing correlation coefficients 0.9954, and 0.995 respectively in the acceptance limits. %RSD for repeatabilities, intermediate precisions and accuracies were also found lower. 
